What is retatrutide?
Retatrutide is a synthetic peptide that has become a significant subject of interest in metabolic pharmacology research. Structurally, it belongs to the incretin-mimetic class of molecules — engineered peptides modelled in part on naturally occurring gut hormones and modified for greater stability and receptor engagement.
What distinguishes retatrutide within this class is that it is a triple receptor agonist. Rather than acting on a single hormonal pathway, it is designed to engage three distinct receptor systems simultaneously. This multi-target design is the central reason the compound has attracted attention in the scientific literature and in ongoing clinical research.
On this page, retatrutide is discussed purely as a research chemical. It is described in neutral scientific terms and is not presented as a medicine, a treatment, or a product for human use of any kind.
The three receptor targets
Retatrutide is characterised in the literature as an agonist at three receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Each of these is a well-studied component of metabolic signalling.
The GLP-1 (glucagon-like peptide-1) receptor is part of the incretin system and has been extensively studied for its role in glucose-dependent insulin signalling and satiety pathways. The GIP (glucose-dependent insulinotropic polypeptide) receptor is the second incretin receptor and is studied for its complementary influence on insulin dynamics and lipid handling.
The glucagon receptor is the element that most clearly separates retatrutide from earlier compounds. Glucagon signalling is studied for its influence on hepatic glucose output and energy expenditure. Combining agonism at this receptor with the two incretin receptors is what defines retatrutide's triple-agonist profile in the research context.
Why triple agonism is of research interest
The scientific interest in retatrutide is best understood by comparison with earlier incretin compounds. Semaglutide, for example, is studied as a single GLP-1 receptor agonist. Tirzepatide is characterised as a dual agonist, engaging both the GLP-1 and GIP receptors.
Retatrutide extends this progression by adding glucagon receptor agonism to the two incretin targets. Researchers are interested in whether engaging three complementary pathways at once produces pharmacological effects that differ meaningfully from single- or dual-target molecules. This is framed in the literature as a question of receptor pharmacology, not as a claim of superiority.
Because of this design, retatrutide is frequently referenced as a point of comparison in metabolic research and has been studied in phase-2 clinical research. Any references here to clinical study describe the research process itself and are not an offer of benefit to any individual.
Molecular identity
Retatrutide is identified in chemical databases under CAS number 2381089-83-2. It is a synthetic peptide with a molecular weight of approximately 4731 Da, reflecting a relatively large and structurally complex molecule compared with small-molecule research chemicals.
Like other engineered incretin-class peptides, its sequence includes modifications intended to improve stability and receptor binding relative to the native hormones it is modelled on. These structural details are what allow it to act across the three receptor systems described above.
For laboratory reference, the CAS number and molecular weight provide the clearest way to confirm compound identity, and reputable suppliers publish certificate-of-analysis data against these identifiers.
How retatrutide is supplied for research
For research applications, retatrutide is typically supplied as a lyophilised (freeze-dried) powder. Lyophilisation removes water from the peptide, which improves stability and shelf life during storage and transit.
Peptides of this type are generally stored cold, and the lyophilised form is commonly kept frozen for longer-term storage, with reconstituted material handled under refrigeration according to standard laboratory practice. Certificate-of-analysis documentation, confirming identity and purity, is a standard expectation for research-grade material.
This page does not describe reconstitution volumes, handling quantities, or any form of preparation or use. Those decisions sit entirely with the qualified researcher and fall outside the scope of an educational overview.
Research-use disclaimer
Retatrutide is offered and described strictly as a research compound for laboratory and research use only. It is not a medicine, a supplement, or a product intended for human or veterinary consumption, and nothing on this page should be interpreted as medical or therapeutic advice.
All information here is provided for general educational and scientific reference. Anyone working with research chemicals is responsible for ensuring compliance with all applicable laws, institutional policies, and safe-handling practices in their jurisdiction.
Frequently asked
What type of molecule is retatrutide?
Retatrutide is a synthetic peptide in the incretin-mimetic class. It is characterised in the literature as a triple receptor agonist, meaning it is designed to engage three metabolic receptor systems at once.
Which receptors does retatrutide target?
It is studied as an agonist at three receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. The addition of glucagon receptor agonism is what distinguishes it from single- and dual-agonist compounds.
How does retatrutide differ from semaglutide and tirzepatide?
In receptor-pharmacology terms, semaglutide is studied as a single GLP-1 agonist and tirzepatide as a dual GLP-1 / GIP agonist. Retatrutide adds a third target, the glucagon receptor, making it a triple agonist in the research literature.
What are retatrutide's key identifiers?
Retatrutide is listed under CAS number 2381089-83-2 with a molecular weight of approximately 4731 Da. These identifiers are the standard way to confirm compound identity against certificate-of-analysis data.
How is research-grade retatrutide supplied and stored?
It is typically supplied as a lyophilised (freeze-dried) powder and stored cold, with the lyophilised form commonly kept frozen for longer-term storage. It is intended for laboratory research use only, not for human use.